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Abstract
Purpose Dronedarone is a benzofuran derivative with a pharmacological profile similar to amiodarone but has a more
rapid onset of action and a much shorter half-life (13–19 h).
Our goal was to evaluate the efficacy of dronedarone in atrial
fibrillation (AF) patients using dual-chamber pacemakers capable of quantifying atrial fibrillation burden.
Methods Pacemakers were adjusted to optimize AF detection.
Patients with AF burden >1 % were randomized to
dronedarone 400 mg twice daily (BID) or placebo. Pacemakers were interrogated after 4 and 12 weeks of treatment.
The primary endpoint was the change in AF burden from
baseline over the 12-week treatment period. Patients with
permanent AF, severe/recently decompensated heart failure,
and current use of antiarrhythmic drugs were excluded. AF
burden was assessed by a core laboratory blinded to treatment
assignment.
Results From 285 patients screened, 112 were randomized
(mean age 76 years, 60 % male, 84 % hypertensive, 65 %

with sick sinus syndrome, 26 % with diabetes mellitus type II,
15 % with heart failure). Baseline mean (SEM) AF burden
was 8.77 % (0.16) for placebo and 10.14 % (0.17) for
dronedarone. Over the 12-week study period, AF burden
compared to baseline decreased by 54.4 % (0.22) (P =
0.0009) with dronedarone and trended higher by 12.8 %
(0.16) (P=0.450) with placebo. The absolute change in burden was decreased by 5.5 % in the dronedarone group and
increased by 1.1 % in the placebo group. Heart rate during AF
was reduced to approximately 4 beats/min with dronedarone
(P=0.285). Adverse events were higher with dronedarone
compared to placebo (65 vs 56 %).
Conclusions Dronedarone reduced pacemaker-assessed the
relative AF burden compared to baseline and placebo by over
50 % during the 12-week observation period.
Keywords Atrial fibrillation . Dronedarone . Pacemaker .
Burden
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1 Introduction
There is a need to develop safe and effective antiarrhythmic
agents for the treatment of atrial fibrillation (AF) [1].
Dronedarone HCl, a benzofuran derivative with a pharmacologic profile similar to amiodarone [2–5], was approved by the
Food and Drug Administration in 2009. In the USA, it is
indicated to reduce the risk of hospitalization for AF in patients in sinus rhythm with a history of paroxysmal or persistent AF [6]. Results from key trials involving nearly 6000

70

patients demonstrated that dronedarone reduces AF recurrence and the composite of CV hospitalization and death in
non-permanent AF [7, 8]. Dronedarone possesses all four
Vaughan-Williams antiarrhythmic properties, with blockade
of sodium channels, noncompetitive antiadrenergic activity,
prolongation of the action potential and refractory periods,
and calcium antagonist properties [2, 5, 6]. Compared to
amiodarone, dronedarone lacks iodine, is less lipophilic, and
has a shorter half-life (13–19 h vs ~58 days for amiodarone),
thereby decreasing accumulation in tissue [5, 6, 9].
Dronedarone has a low systemic bioavailability, which increases up to 15 % when the drug is administered after a fatty
meal. After repeated administration of 400 mg twice daily
(BID), steady state is reached within 4 to 8 days [6, 10].
Dronedarone is metabolized by CYP3A enzyme system [6,
10].
The efficacy of antiarrhythmic drugs in patients with AF
has been tested using the time to first recurrence of symptomatic AF [11–14]; AF events, however, frequently occur in
clusters, thus questioning the validity of this endpoint
[15–17]. In addition, time to first recurrence data fail to
quantify AF burden (i.e., percent of time in AF), frequency,
and number of episodes [12], all of which may carry a different prognosis. Asymptomatic episodes are common and complicate the assessment and may in fact represent the majority
of AF episodes and may be associated with mortality and
stroke risk [18, 19]. The availability of continuous monitoring
permits documentation of frequency, duration, time of onset,
and rate of AF as well as AF burden [17, 20, 21]. Patients with
accepted indications for permanent pacemakers, particularly
patients with sinus node disease, are at significant risk for AF,
with prevalence rates of up to and over 50 % in some studies
[22–24]. The Effects of Dronedarone on Atrial Fibrillation
Burden in Subjects with Permanent Pacemakers (HESTIA;
ClinicalTrials.gov number, NCT01135017) evaluates the impact of dronedarone on AF burden in patients with AF and
permanent cardiac pacemakers.

2 Methods
The intent of HESTIA was to enroll 290 AF patients with an
interim analysis when 150 patients completed. Recruitment
was slow and the study was terminated after enrollment of 112
patients. For entry, patients had to be at least 21 years of age
with documented AF and sinus rhythm within the previous
6 months. Patients were included if one of the following CV
risk factors were present: age ≥70 years, hypertension, diabetes mellitus, prior CV accident (stroke or transient ischemic
attack) or systemic embolism, or M-mode or 2D echocardiography findings showing a left atrium diameter ≥50 mm or
left ventricular ejection fraction less than ≤0.40 within the
prior 12 months.
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HESTIA was a placebo-controlled, double-blind, randomized, multicenter trial designed to assess the effects of
dronedarone 400 mg BID versus placebo on AF burden in
patients with a permanent pacemaker. Following patient consent, pacemakers were programmed to optimize atrial sensing.
First, far-field R wave oversensing at maximum atrial sensitivity was assessed both during ventricular pacing and during
ventricular sensing (if feasible). If far-field R wave
oversensing was present, post-ventricular atrial blanking period (PVAB) was increased 25 ms beyond the longest far-field
R wave signal. If there was no far-field R wave oversensing,
PVAB was programmed to nominal setting. Final atrial sensitivity was set between 0.25 to 0.35 mV or above if needed
(minimum allowable sensitivity was 0.75 mV). Patients were
excluded if atrial sensing was <1 mV. The pacemakers were
programmed to DDD or MVP mode and ventricular sensing
was promoted by programming long AV delay if intrinsic
conduction allowed. Mode switch rate was set to 200 bpm
and the maximum number of bipolar atrial electrograms
(EGMs) was stored for these episodes in the pacemakers.
EGMs were reviewed as a quality control measure to ensure
that they were due to atrial arrhythmias and that mode
switches were accurate. Atrial overdrive pacing or atrial tachycardia therapies were programmed off. The study was conducted with support of a Pacemaker Core Laboratory (PERFUSE, Boston, MA) to ensure quality control. The core laboratory reviewed all interrogation reports and electrograms to
ensure that pacemaker settings were consistent with protocol
requirements and that pacemakers were accurately recording
AF (i.e., atrial high rate episodes).
Patients were allowed treatment with concomitant medications based on dronedarone prescribing recommendations.
Where possible, digoxin was either discontinued or halved.
Treatment with Vaughan-Williams class I and III antiarrhythmics was prohibited. Use of amiodarone was prohibited within 4 weeks of screening.
Patients were randomized 1:1 to dronedarone or placebo
and treated for 12 weeks. The trial was conducted in accordance with all applicable ethical and good clinical practice
principles, including the Declaration of Helsinki. Written informed consent was obtained from all participants.
All subjects had a dual-chamber pacemaker placed for an
approved clinical indication from which AF burden was determined. There was an initial 4-week screening period
(Fig. 1). AF burden was defined as arrhythmia time/24 h
(e.g., 6 h of AF arrhythmia time would be 25 %). The AF
burden had to be at least 1 % during the 4-week screening
period off anti-arrhythmic therapy for study eligibility. For
eligible patients, the AF burden during the screening period
constituted the baseline AF burden. Pacemaker interrogations
were also performed at 4 and 12 weeks after randomization. A
final follow-up visit was performed 14 weeks after
randomization.
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Fig. 1 Trial design. AF atrial
fibrillation, BID twice daily, EGM
electrogram, PPM permanent
pacemaker

The primary objective of this study was the effect of
dronedarone on AF burden. Secondary objectives included
the effects of dronedarone on ventricular rate during AF;
patient-perceived AF burden; and symptom severity as reported by patients using the Atrial Fibrillation Severity Scale
(AFSS). The number of electrical cardioversions and manual
overdrive pacing events during treatment were collected.
An independent Data Monitoring Committee monitored
safety, deaths, hospitalizations, and adverse events leading to
drug discontinuation. Areas of special interest were congestive heart failure (CHF), diagnosis of interstitial lung disease,
skin disorders, and peripheral neuropathy, the latter three are
well known complications of amiodarone. CHF was assessed
at screening and throughout the study. The planned sample
size of 290 was estimated to have 70 % power to detect a
reduction in mean AF burden of 30 % relative to the placebo
group. The early termination of the study at 112 patients
randomized reduced the power to detect treatment effects to
under 50 %. The modified intent-to-treat (mITT) population
included all patients who were randomized, treated with ≥1
dose of dronedarone, and had ≥1 post-baseline assessment of
AF burden. The safety population was defined as the randomized population who received ≥1 dose of study medication.
AF burden during the 12-week treatment period was analyzed
in log-scale with adjustment for the baseline to compare AF
burden between the dronedarone and placebo arms due to the
non-normal distribution of AF burden. An analysis of covariance (ANCOVA) model was applied to the log-transformed
AF burden data. The difference between treatment arms was
estimated by the least squares mean method and was significant if the two-sided p value of the test was <0.05.
For secondary efficacy analyses, AF burden in the first
4 weeks and after 4 weeks of treatment was analyzed using
the statistical method described for the primary efficacy variable and the average ventricular rate during AF episodes and
the Atrial Fibrillation Severity Scale (AFSS) scores were
analyzed without transformation using an ANCOVA model
with treatment arm as a fixed effect term and the baseline
value as a covariate. Electrical cardioversion (or overdrive
pacing) was recorded.

3 Results
Two hundred and eighty-five subjects were screened; 112
(Fig. 2 and Table 1) were randomized to receive treatment.
Cardiovascular history of randomized subjects included hypertension in 84 %, sick sinus syndrome in 65 %, and congestive heart failure in 15 % of patients (Table 2). At randomization, 82 % were prescribed rate-lowering medications and
73 % oral anticoagulants (Table 3). Two subjects did not have
a post-randomization interrogation of their pacemaker. Both
were excluded from the primary efficacy analysis.
Median duration of treatment was 12 weeks. Ninety-four
subjects completed the study, and 18 subjects discontinued
treatment due to the investigator’s or subject’s decision. Discontinuations due to an adverse event in the dronedarone
group (14 %) exceeded those in the placebo group (6 %).
Over the 12-week treatment period, mean AF burden increased from 8.8 % (0.16) to 9.9 % (0.20) (increase of 12.8 %
(0.16); P=0.450) in the placebo group and decreased from
10.1 % (0.17) to 4.6 % (0.29) (decrease of 54.4 % (0.22); P=
0.0009) in the dronedarone group. The absolute changes in AF
burden from baseline increased by 1.1 % in the placebo group
and decreased by 5.5 % in the dronedarone group. Compared to
placebo, AF burden in the dronedarone group was decreased by
59.1 % (0.28 %) (P=0.0015; Fig. 3). AF burden changes with
dronedarone compared to placebo in secondary efficacy analyses were consistent with the overall result (weeks 1–4, 63.2 %
(0.29) reduction, P=0.0009; weeks 5–12, 60.3 % (0.30) reduction, P=0.003). The distribution of baseline versus weeks 1–12
AF burden in treated patients is shown in Fig. 4.
The mean ventricular rate during AF was approximately
4 bpm lower in the dronedarone treatment group compared to
placebo (P=0.285). AFSS changes from baseline were not
significantly different between groups (Table 4). Only one
patient in the placebo group was cardioverted.
Treatment-emergent adverse events were common in both
groups (dronedarone, 64.9 %; placebo, 56.4 %); most were
gastrointestinal (Table 5). Treatment-emergent serious adverse
events occurred in 14 patients (7 in each treatment group).
Serious adverse events in the dronedarone group included
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Fig. 2 Patient disposition at end
of study. AFB atrial fibrillation
burden, D/C discontinuation, ITT
intent to treat

congestive heart failure, peripheral neuropathy, ocular discomfort, presyncope, muscle rupture, and cardiomyopathy.
More patients in the dronedarone group discontinued treatment due to adverse events compared with placebo (8
[14.0 %] vs 3 [5.5 %], respectively). There was no evidence
of dronedarone-induced ventricular tachycardia and there
were no deaths, strokes, or major bleeding events in the study.

4 Discussion
The major finding was a 59 % relative reduction of AF burden
with dronedarone compared to placebo (P=0.0015). In the
placebo group, the mean (geometric) AF burden increased
from 8.8 to 9.9 % during the treatment period, whereas in
Table 1

Patient baseline demographics
Placebo
(n=55)

Age, mean (SD), years

74.5 (9.5)

Dronedarone All
(n=57)
(N=112)
77.3 (8.6)

Men, n (%)
Hispanic, n (%)
Race, n (%)
Caucasian/White

38 (69.1)
0

29 (50.9)
1 (1.8)

50 (90.9)

54 (94.7)

Black
Asian/Oriental
Body mass index ≥30 kg/m2
Creatinine clearance, mean
(SD), mL/min

5 (9.1)
0
24 (43.6)
73.2 (27.2)

2 (3.5)
1 (1.8)
22 (38.6)
66.1 (31.4)

SD standard deviation

75.9
(9.1)
67 (59.8)
1 (0.9)
104
(92.9)
7 (6.3)
1 (0.9)
46 (41.1)
69.6
(29.5)

the dronedarone group, the mean (geometric) AF burden was
decreased from 10.1 to 4.6 %, an absolute reduction of 5.5 %.
The effect was consistent over the 12-week duration of treatment. Average ventricular rate during AF was slightly (4 bpm)
lower in the dronedarone group, but these differences were not
statistically significant. There were no statistically significant
differences in the AFSS. One patient was cardioverted.
Consistent with the known profile of dronedarone, there
was an increase in gastrointestinal events. Serious adverse
events and discontinuations due to adverse events were infrequent but occurred more often in the dronedarone group.
There were no deaths in the study.
Two large multicenter, randomized, placebo-controlled
studies evaluated the efficacy of dronedarone on AF recurrence [7, 8]. In the pooled analysis of the European Trial in
Atrial Fibrillation or Flutter Patients Receiving Dronedarone
for the Maintenance of Sinus Rhythm (EURIDIS,
NCT00259428) and the American-Australian-African Trial
with Dronedarone in Atrial Fibrillation or Flutter Patients for
the Maintenance of Sinus Rhythm (ADONIS,
NCT00259376), dronedarone significantly delayed the time
to first recurrence of AF during the 12-month study period by
approximately 25 % (P<0.001 vs placebo), with an absolute
difference in recurrence rate of ~11 % [8].
Use of pacemaker determined AF burden has been the
subject of several prior studies and has potentially important
clinical implications. A recent trial of patients with bradycardia and a history of AF receiving pacemakers indicated that
total AF burden had a significant but weak correlation with
cardiac hospitalization rates [25]. Although total AF burden is
typically used as an endpoint in device trials such as the Atrial
Therapy Efficacy and Safety Trial (ATTEST) [21, 26–29], it
may also be a useful endpoint for antiarrhythmic medications.
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Cardiovascular history of randomized patients

Table 3

Summary of baseline medications

Placebo Dronedarone All
(n=55) (n=57)
(N=112)
Hypertension

45

(81.8)

Beta blocking agents (except sotalol) 35
49
(86.0)

94 (83.9)
Sick sinus syndrome

37

(67.3)
36
(63.2)

73 (65.2)
Coronary artery disease

24

15

(27.3)
20
(35.1)

35 (31.3)
Atrioventricular block above first
degree

13

(23.6)
9
(15.8)

22 (19.6)
Congestive heart failure

(63.6)

40
(70.2)

33

(60.0)

24
(42.1)

38

(69.1)

44
(77.2)

82 (73.2)
Diuretics

25

(45.5)

21
(36.8)

46 (41.1)
Aspirin

26

(47.3)

19
(33.3)

45 (40.2)
Statins

34

(61.8)

32
(56.1)

12

(21.8)

8 (14.0)

12

(21.8)

10
(17.5)

10

(18.2)

5 (8.8)

75 (67.0)
Angiotensin-converting enzyme
inhibitors or angiotensin II
receptor antagonists
57 (50.9)
Oral anticoagulant

(43.6)
16
(28.1)

40 (35.7)
Syncope

Placebo Dronedarone All
(n=55) (n=57)
(N=112)

6 (10.9) 11 (19.3)

Non-rheumatic valvular heart disease 7 (12.7)

9 (15.8)

Myocardial infarction

9 (16.4)

6 (10.5)

Ischemic stroke
Peripheral arterial disease
Transient ischemic attack
Supra-ventricular tachycardia other
than atrial fibrillation/atrial flutter
Deep vein thrombosis
Stroke of unknown origin
Ischemic dilated cardiomyopathy
Torsades de pointe
Ventricular fibrillation

6 (10.9)
7 (12.7)
5 (9.1)
3 (5.5)

5 (8.8)
3 (5.3)
3 (5.3)
4 (7.0)

17
(15.2)
16
(14.3)
15
(13.4)
11 (9.8)
10 (8.9)
8 (7.1)
7 (6.3)

3 (5.5)
1 (1.8)
2 (3.6)
1 (1.8)
1 (1.8)

3 (5.3)
4 (7.0)
2 (3.5)
0
0

6 (5.4)
5 (4.5)
4 (3.6)
1 (0.9)
1 (0.9)

66 (58.9)
Calcium antagonists with heart rate
lowering effects
20 (17.9)
Digitalis
22 (19.6)
Other chronic antiplatelet therapy
15 (13.4)
All data are expressed as n (%)

All data are expressed as n (%)

use of a pacemaker core lab to ensure that pacemakers were
appropriately set to study requirements and that pacemakers
were accurately recording AF. Last, because HESTIA was
placebo-controlled, patients with more severe AF symptoms
were excluded. Low baseline AFSS burden and symptom
scores reflect this and may have mitigated finding significant
changes in the AFSS despite significant reductions in AF
burden observed in the study.

The Paroxysmal Atrial Fibrillation Study with Continuous
Atrial Fibrillation Logging (PASCAL, NCT00389792) trial
found up to a 74 % reduction in AF burden with budiodarone
in an investigational dose ranging study [17].
The study had several limitations. First, study enrollment
was below goals (290 planned vs 112 actual patients with
interim analysis planned at 150 patients) because of the difficulty in finding non-permanent AF patients with at least 1 %
AF burden on initial screening and during the 4-week baseline
period. The study, however, was analyzed as originally
planned with the primary endpoint achieving a highly significant (P=0.0015) outcome. A second limitation is the use of
mode switches to assess AF burden with the risks of under or
oversensing. Efforts were made to mitigate this risk including

Fig. 3 Baseline (week −4 to randomization), week 4, and week 12 (end
of treatment) mean geometric AF burden. The primary efficacy result was
the least mean square (LMS) difference in AF burden between placebo
and dronedarone at week 12 (59.13 (0.28); P=0.0015. Similar results
were observed at week 4

74

J Interv Card Electrophysiol (2015) 42:69–76
Table 5

Fig. 4 Plot of AF burden at baseline versus AF burden weeks 1–12.
Points above the line represent increases in AF burden post-baseline and
points below represent reductions in AF burden. Placebo is represented as
red circles and dronedarone as black squares

The HESTIA study has important implications on design
of future trials of antiarrhythmic drugs for AF. A post hoc
calculation of study power based on our study findings was
>95 %, underscoring the sensitivity of continuous ECG monitoring for assessing AF. In comparison, the EURIDIS and
ADONIS studies required >500 patients each to detect a 25 %
reduction in the rate of AF recurrence (at 12 months) with
dronedarone compared to placebo with 90 % power. Continuous ECG monitoring also provides a more complete characterization of AF patterns compared with traditional time to
Table 4

Summary of Atrial Fibrillation Severity Scale (AFSS)

AF burden
Baseline mean (SD)
Post-baseline mean (SD)
Change from baseline, mean
(SD)
Treatment difference, LS mean
(SE)a
P value
AF symptoms
Baseline mean (SD)
Post-baseline mean (SD)
Change from baseline, mean
(SD)
Treatment difference, LS mean
(SE)a
P value
a

From ANCOVA model

Placebo
(N=55)

Dronedarone
(N=55)

13.72 (4.59)
13.30 (5.40)
−1.04 (3.22)

12.76 (4.62)
12.48 (5.45)
−0.68 (4.71)

0.14 (0.981)

Treatment-emergent adverse events

Overview of treatment-emergent
adverse events
Patients with any treatmentemergent adverse event
Patients with any treatmentemergent serious adverse event
Patients with any treatment-emergent
adverse event leading to death
Patients with any treatment-emergent
adverse event leading to permanent
treatment discontinuation
Treatment-emergent adverse event of
special interest
Congestive heart failure
Treatment-emergent adverse events
by primary system organ class
Gastrointestinal disorders
Respiratory, thoracic, and mediastinal
disorders
Nervous system disorders
Infections and infestations
Cardiac disorders
Metabolism and nutrition disorders
Vascular disorders
Psychiatric disorders
Eye disorders
Ear and labyrinth disorders
Skin and subcutaneous tissue disorders
Musculoskeletal and connective
tissue disorders
Renal and urinary disorders
Immune system disorders
Hepatobiliary disorders

Placebo
(n=55)

Dronedarone
(n=57)

31 (56.4)

37 (64.9)

7 (12.7)

7 (12.3)

0

0

3 (5.5)

8 (14.0)

2 (3.6)

3 (5.3)

10 (18.2)
7 (12.7)

17 (29.8)
8 (14.0)

6 (10.9)
8 (14.5)
3 (5.5)
3 (5.5)
2 (3.6)
2 (3.6)
1 (1.8)
2 (3.6)
2 (3.6)
4 (7.3)

7 (12.3)
6 (10.5)
5 (8.8)
3 (5.3)
3 (5.3)
1 (1.8)
1 (1.8)
1 (1.8)
1 (1.8)
1 (1.8)

1 (1.8)
1 (1.8)
1 (1.8)

1 (1.8)
0
0

All data are expressed as n (%). Treatment-emergent adverse events
include all patients randomized and that received at least one dose of
study drug

first recurrence assessments, and also offers a sensitive method of detecting ventricular arrhythmias.

0.8902
8.47 (6.97)
8.06 (7.11)
−0.28 (4.88)
−0.49 (0.980)
0.6216

8.36 (6.83)
7.42 (7.48)
−0.72 (5.66)

5 Conclusion
The HESTIA study was designed to investigate the effects of
dronedarone on AF burden in a population of patients
experiencing intermittent episodes of AF. Prior to randomization, these patients were in AF an average of 10 % of the time.
Dronedarone reduced the primary endpoint, time in AF, by
slightly more than half (P<0.005). This effect was consistent
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over the 12-week duration of treatment. Safety findings were
consistent with the known profile of dronedarone.
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